Adherence to an antiretroviral regimen is imperative to achieve virologic control. A number of factors contribute to adherence, including number of pills per day, frequency of doses, and adverse effect profile.55–58 Virologic control can contribute to improved quality of life in patients infected with HIV; this in turn can improve antiretroviral adherence.1,55 With available once daily dosing, a new fixed dose combination with abacavir and lamivudine, and a relatively low adverse effect profile, DTG meets these characteristics.